Histopathological classification and immunophenotyping of spontaneous canine lymphoma in Bangkok metropolitan

Rungsipipat, Anudep; Chayapong, Jutapon; Jongchalermchai, Juliluck; Thongruk, Thunchanok; Manachai, Nawin; Wangnaitham, Supradit; Techangamsuwan, Somporn

doi:10.1007/s00580-012-1600-9

Cited by 3 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Canine lymphoma in this study was classified into three anatomical locations: multicentric, alimentary, and extranodal, multicentric lymphomas have frequently been observed in dogs (Dobson et al 2002;Rungsipipat et al 2012). In this study, B-cell lymphoma was found in 69.57% of cases, whereas T-cell lymphoma was detected in the remaining 30.43%.…”

Section: Discussionmentioning

confidence: 69%

“…Four to six µm-thick sections were immunophenotypically classified using anti-CD3, anti-Pax5, and anti-CD79a, to identify T-and B-cell lineages, respectively. The immunohistochemical protocol was modified from Rungsipipat et al (2012). Briefly, antigen retrieval for CD3 was achieved by heating slides with 10mM citrate buffer (pH 6.0) in a microwave oven.…”

Section: Methodsmentioning

confidence: 99%

“…Canine lymphoma was found to represent approximately 1.94% of all canine tumours and 76.6% of all hematopoietic neoplasms in Bangkok, Thailand (Rungsipipat et al 2012), similarly as in other countries (Weiss 2006;Regan et al 2013). Canine malignant lymphomas are normally derived from a clonal expansion of neoplastic B or T lymphocytes.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Pax5 as a potential candidate marker for canine B-cell lymphoma

Sirivisoot¹,

Techangamsuwan²,

Tangkawattana³

et al. 2017

Vet. Med. - Czech

View full text Add to dashboard Cite

ABSTRACT:Immunophenotyping is a valuable method for prognosis in canine malignant lymphoma. The general B-cell marker is CD79a; however, Pax5 or B-cell specific activator protein, a transcription factor that controls B-cell identity and cell maturation, could also be used as a B-cell indicator in canine lymphomas. This study aimed to use Pax5, CD79a and CD3 expression in immunohistochemistry of spontaneous canine lymphomas, in order to carry out diagnosis and histopathological classification according to the World Health Organization guidelines. Forty-six retrospective cases including 33 multicentric, eight extranodal, and five alimentary lymphomas in dogs were immunostained by anti-Pax5 and anti-CD79a antibodies for B-cell identification, and anti-CD3 antibody for T-cell identification. T-cell lymphomas (CD3+/Pax5-/CD79a-) accounted for 30.43% of cases (14/46), and four of the lymphomas (28.57%) presented with CD3+/Pax5-/CD79a+. Conversely, B-cell lymphomas (CD3-/ Pax5+/CD79a+) accounted for 69.57% of cases (32/46) and 12.5% of these (4/32) showed only Pax5-positive cells (CD3-/Pax5+/CD79a-). Therefore, in dogs, Pax5 appears to be a more useful marker for staining all B-cell subtypes compared to CD79a. Immunophenotyping with both Pax5 and CD3 are necessary for lymphoid lineage identification in canine lymphomas.

show abstract

Section: Discussionmentioning

confidence: 69%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Pax5 as a potential candidate marker for canine B-cell lymphoma

Sirivisoot¹,

Techangamsuwan²,

Tangkawattana³

et al. 2017

Vet. Med. - Czech

View full text Add to dashboard Cite

show abstract

“…Immunohistochemistry (IHC) was performed by LSAB method for lymphoma cell type classification. Immunophenotype was done by using specific antibodies against T-cell (CD 3) (Rungsipipat et al, 2012) and B-cell (CD 79α) (Durham et al, 2012). Briefly, the sections were deparaffinized and antigen retrieval method was performed by using autoclave at 121 0 C for 5 minutes.…”

mentioning

confidence: 99%

Multicentric B-cell Lymphoma and Disseminated Atherosclerosis in a Gelding

Siripoonsub¹

2016

Res. J. Vet. Pract.

View full text Add to dashboard Cite

| A 5-year old, 258-kg-weight, mixed thoroughbred gelding was found acute death with abdominal enlargement caused by hemorrhagic strangulated enteritis and colic. Necropsy and histopathology revealed multicentric lymphoma involving spleen and abdominal lymph nodes, disseminated atherosclerosis of vena cava, aorta and myocardium and metastatic calcification. Immunohistochemistry was performed in order to categorize immunophenotype of T-cell and B-cell lymphoma. This case was diagnosed as multicentric low grade B-cell lymphoma. In addition, pathogenesis of lymphoma associated with disseminated atherosclerosis of this case was discussed.

show abstract

“…Malignant lymphoma is a common hematopoietic tumour in animals, especially in dogs. Canine lymphoma was found to represent approximately 1.94% of all canine tumours and 76.6% of all hematopoietic neoplasms in Bangkok, Thailand (Rungsipipat et al, 2012), similarly as in other countries (Weiss, 2006;Regan et al, 2013). Canine malignant lymphomas are normally derived from a clonal expansion of neoplastic B or T lymphocytes.…”

Section: Introductionmentioning

confidence: 99%

Immunophenotype, Molecular Diagnosis, Minimal Residual Disease, and Multidrug Resistance Protein Expression in Modified Cop, Modified Chop and Rescue Protocols of Treated Canine Lymphomas

Sirivisoot

View full text Add to dashboard Cite

Multicentric lymphoma is the most common hematopoietic tumors in dogs. Both B- or T-lymphocyte clones can originate to lymphoma. A gold standard method to differentiate each lymphocyte lineage is immunohistochemistry (IHC) by detecting specific proteins of B and T cell. A protein marker for T and B cells is CD3 and CD79a, respectively. However, another pan pre B-cell marker is Pax5 or B-cell specific activator protein. It is more specific and sensitive than CD79a because it expresses only in B-cell lymphoma cases. The first purpose of this research was to 1) determine Pax5 expression in canine lymphomas by IHC and compare the results to CD79a and CD3 expression for lymphoid lineage. The result of this study showed that 28 B-cell lymphoma cases expressed both Pax5 and CD79a, nevertheless four cases of B cell illustrated only Pax5 expression. Furthermore, four from ten T-cell lymphoma samples presented dual CD3 and CD79 expression. Therefore, Pax5 has 100% sensitivity and specificity, whereas CD79a has 87.5% sensitivity and 71.4% specificity. Immunocytochemistry (ICC) is easier and cheaper than IHC for immunophenotyping. Clonality assay or PCR for antigen receptor rearrangement (PARR) could diagnose neoplastic lymphocyte clones and additionally detect minimal residual disease (MRD) in canine lymphomas. The second aim of this research was to 2) develop heteroduplex PARR for clonality test from peripheral blood and lymph node cytology and develop ICC for lineage determination compared to IHC using Pax5 and CD3. Immunophenotyping results by ICC and IHC with both Pax5 and CD3 showed strong correlation in 25 samples of B-cell lymphoma and three samples of T-cell lymphomas. When compared the clonality results between heteroduplex PARR and IHC, the percentage agreement was 60%. Thus, heteroduplex PARR could be used as an adjunctive method with IHC or ICC. Canine multicentric lymphoma generally responds well to chemotherapy, but tumor relapse after complete remission is prevalent because of MRD. MRD could assess by only molecular techniques. The third objective of this research was to 3) evaluate MRD from peripheral blood using heteroduplex PARR in canine multicentric B- and T-cell lymphomas during treatment with modified L-COP (L-asparaginase, vincristine, cyclophosphamide, and prednisolone)) and modified L-CHOP (L-asparaginase, vincristine, cyclophosphamide, doxorubicin and prednisolone) for determining treatment efficacy and treatment response between two protocols. MRD negative results showed the correlation to complete remission during treatment and could be useful for predicting treatment efficacy and clinical response. Drug resistance mechanisms is a major cause of treatment failure during treatment or after complete remission in refractory and relapsing canine lymphoma because tumor cells upregulate multidrug resistance protein for efflux toxic drugs out of cells. Two multidrug resistance proteins that have a role in drug resistance mechanism in canine multicentric B- and T-cell lymphoma are P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP). Furthermore, tyrosine kinase inhibitor (TKI) could inhibit Pgp function. The final aim of this research was to 4) develop rescue protocol for refractory/relapsed canine lymphoma with lomustine (CCNU) or L-asparaginase and vincristine concurrent with toceranib phosphate, and asses protein expression levels of Pgp and BCRP from peripheral blood before and after treatment using qRT-PCR. The results showed that toceranib phosphate or TKI with CCNU or L-asparaginase and vincristine tended to decrease the transcription expression levels of Pgp and BCRP when compared the levels prior to and after treatment. Hence, this rescue protocol could be another treatment option in refractory/relapsed canine lymphomas.

show abstract

Histopathological classification and immunophenotyping of spontaneous canine lymphoma in Bangkok metropolitan

Cited by 3 publications

References 15 publications

Pax5 as a potential candidate marker for canine B-cell lymphoma

Pax5 as a potential candidate marker for canine B-cell lymphoma

Multicentric B-cell Lymphoma and Disseminated Atherosclerosis in a Gelding

Immunophenotype, Molecular Diagnosis, Minimal Residual Disease, and Multidrug Resistance Protein Expression in Modified Cop, Modified Chop and Rescue Protocols of Treated Canine Lymphomas

Contact Info

Product

Resources

About